Jaguar Health Reports Crofelemer Reduces Parenteral Support in Pediatric Intestinal Failure Study

Reuters

01/06

Jaguar Health Reports Crofelemer Reduces Parenteral Support in Pediatric Intestinal Failure Study

Jaguar Health Inc. announced new results from an ongoing independent proof-of-concept study evaluating crofelemer in pediatric patients in the United Arab Emirates with intestinal failure due to short bowel syndrome (SBS-IF) and microvillus inclusion disease (MVID). The initial results, which were presented on November 8, 2025, at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting, demonstrated reductions in parenteral support (PS) ranging from 12 to 37 percent in treated patients. In addition, Jaguar and its subsidiary Napo Pharmaceuticals are conducting placebo-controlled clinical trials of crofelemer in adult SBS-IF patients in the EU and in pediatric MVID patients in the US, EU, and Middle East. Crofelemer has received Orphan Drug Designation from the U.S. FDA and the European Medicines Agency for both SBS and MVID.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1124314) on January 06, 2026, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2601281899"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601281899\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601281899?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601281899","market":"fut","top_or_hot":-1,"title":"Jaguar Health Reports Crofelemer Reduces Parenteral Support in Pediatric Intestinal Failure Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jaguar Health Reports Crofelemer Reduces Parenteral Support in Pediatric Intestinal Failure Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jaguar Health Inc. announced new results from an ongoing independent proof-of-concept study evaluating crofelemer in pediatric patients in the United Arab Emirates with intestinal failure due to short bowel syndrome (SBS-IF) and microvillus inclusion disease (MVID). The initial results, which were presented on November 8, 2025, at the <a href=\"https://laohu8.com/S/FNCSF\">North American</a> Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting, demonstrated reductions in parenteral support (PS) ranging from 12 to 37 percent in treated patients. In addition, Jaguar and its subsidiary Napo Pharmaceuticals are conducting placebo-controlled clinical trials of crofelemer in adult SBS-IF patients in the EU and in pediatric MVID patients in the US, EU, and Middle East. Crofelemer has received Orphan Drug Designation from the U.S. FDA and the European Medicines Agency for both SBS and MVID.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1124314) on January 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jaguar Health Reports Crofelemer Reduces Parenteral Support in Pediatric Intestinal Failure Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJaguar Health Reports Crofelemer Reduces Parenteral Support in Pediatric Intestinal Failure Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-06 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jaguar Health Reports Crofelemer Reduces Parenteral Support in Pediatric Intestinal Failure Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jaguar Health Inc. announced new results from an ongoing independent proof-of-concept study evaluating crofelemer in pediatric patients in the United Arab Emirates with intestinal failure due to short bowel syndrome (SBS-IF) and microvillus inclusion disease (MVID). The initial results, which were presented on November 8, 2025, at the <a href=\"https://laohu8.com/S/FNCSF\">North American</a> Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting, demonstrated reductions in parenteral support (PS) ranging from 12 to 37 percent in treated patients. In addition, Jaguar and its subsidiary Napo Pharmaceuticals are conducting placebo-controlled clinical trials of crofelemer in adult SBS-IF patients in the EU and in pediatric MVID patients in the US, EU, and Middle East. Crofelemer has received Orphan Drug Designation from the U.S. FDA and the European Medicines Agency for both SBS and MVID.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1124314) on January 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JAGX","symbol_name":"Jaguar Animal Health, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL5y78zh:1","article_id":"2601281899","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601281899","pubTimestamp":1767708072,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jaguar Health Inc. announced new results from an ongoing independent proof-of-concept study evaluating crofelemer in pediatric patients in the United Arab Emirates with intestinal failure due to short bowel syndrome  and microvillus inclusion disease . The initial results, which were presented on November 8, 2025, at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition  Annual Meeting, demonstrated reductions in parenteral support  ranging from 12 to 37 percent in treated patients. In addition, Jaguar and its subsidiary Napo Pharmaceuticals are conducting placebo-controlled clinical trials of crofelemer in adult SBS-IF patients in the EU and in pediatric MVID patients in the US, EU, and Middle East. Crofelemer has received Orphan Drug Designation from the U.S. FDA and the European Medicines Agency for both SBS and MVID.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ac","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JAGX":"Jaguar Animal Health, Inc.","BK4007":"制药"},"translate_title":"Jaguar Health报告Crofelemer减少儿科肠外支持研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAGX":0.9},"content_text":"Jaguar Health Reports Crofelemer Reduces Parenteral Support in Pediatric Intestinal Failure Study\n    \n\n        Jaguar Health Inc. announced new results from an ongoing independent proof-of-concept study evaluating crofelemer in pediatric patients in the United Arab Emirates with intestinal failure due to short bowel syndrome (SBS-IF) and microvillus inclusion disease (MVID). The initial results, which were presented on November 8, 2025, at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting, demonstrated reductions in parenteral support (PS) ranging from 12 to 37 percent in treated patients. In addition, Jaguar and its subsidiary Napo Pharmaceuticals are conducting placebo-controlled clinical trials of crofelemer in adult SBS-IF patients in the EU and in pediatric MVID patients in the US, EU, and Middle East. Crofelemer has received Orphan Drug Designation from the U.S. FDA and the European Medicines Agency for both SBS and MVID.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1124314) on January 06, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}